

PRODUCT	DISEASE	PIPELINE			
		PHASE 1	PHASE 2	PHASE 3	COMMERCIAL
TTR					
ONPATTRO® (patisiran)	hATTR Amyloidosis with Polyneuropathy				
AMVUTTRA® (vutrisiran)	ATTR Amyloidosis with Cardiomyopathy and hATTR Amyloidosis with Polyneuropathy				
Nucresiran	ATTR Amyloidosis with Cardiomyopathy				
Nucresiran	hATTR Amyloidosis with Polyneuropathy				
RARE					
GIVLAARI® (givosiran)	Acute Hepatic Porphyria (AHP)				
OXLUMO® (lumasiran)	Primary Hyperoxaluria Type 1 (PH1)				
Qfitlia™ (fitusiran)	Hemophilia A or B ¹				
Cemdisiran (+/- Pozelimab)	Myasthenia Gravis ¹				
Cemdisiran (+ Pozelimab)	Paroxysmal Nocturnal Hemoglobinuria ¹				
ALN-6400 (PLG)	Bleeding Disorders				
AG-236 (ALN-TMP)	Polycythemia Vera ¹				
ALN-CFB	Paroxysmal Nocturnal Hemoglobinuria ¹				
CARDIOVASCULAR					
Leqvio® (inclisiran)	Hypercholesterolemia ¹				
Zilebesiran	Hypertension ²				
Zilebesiran + REVERSIR	Hypertension ²				
METABOLIC					
Rapirosiran (ALN-HSD)	Metabolic Dysfunction-Associated Steatohepatitis (MASH) ¹				
ALN-ANG3	Diabetic Kidney Disease ¹				
ALN-4324 (GRB14)	Type 2 Diabetes Mellitus				
ALN-2232 (ACVR1C)	Obesity & Weight Management				
ALN-PNP	Non-Alcoholic Fatty Liver Disease (NAFLD) ³				
ALN-APOC3	Dyslipidemia ¹				
ALN-CIDEB	Metabolic Dysfunction-Associated Steatohepatitis (MASH) ¹				
NEUROLOGIC					
Mivelsiran (ALN-APP)	Cerebral Amyloid Angiopathy (CAA)				
Mivelsiran (ALN-APP)	Alzheimer's Disease				
ALN-HTT02	Huntington's Disease ⁴				
ALN-5288 (MAPT)	Alzheimer's Disease ⁴				
ALN-SOD	SOD1 Amyotrophic Lateral Sclerosis (ALS) ³				
ALN-SNCA	Parkinson's Disease ³				
OTHER					
Cemdisiran (+/- Pozelimab)	Geographic Atrophy ¹				
Elebsiran (+Tobevibart)	Hepatitis D Virus Infection ¹				
ALN-BCAT	Hepatocellular Carcinoma				
ALN-F1202	Healthy Volunteers ¹				

¹ Out-licensed with milestones and/or royalties
³ Partner-led with profit split

² Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US
⁴ Partnered, Alnylam-led with profit split